Sun Pharma Q2FY25 net profit was up 28% YoY on 11% revenue growth. FY25 R&D investment guidance cut due to deferred clinical trials. Specialty business momentum lacking without immediate drivers.
What is covered in the Full Insight:
Financial Performance Overview
Specialty Business Challenges
Pipeline Developments and Collaborations
Market Position and Competition
Future Outlook and Investment Considerations
SUMMARY
(Sign Up to Access)
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
Unlock research summaries
Follow top, independent analysts
Receive personalised alerts
Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.